CIK 0001764974
TSBX Turnstone Biologics Corp.
Insider trading from SEC Form 4. Last filing Aug 12, 2025.
Turnstone Biologics Corp. (TSBX) has 4 SEC Form 4 filings on file from 4 insiders, the latest filed on Aug 12, 2025. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
Last 90 days
Signals
Open-market buys and sells at Turnstone Biologics Corp., scored.
Transactions
Every row filed, 12 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 8, 2025 | Orbimed Advisors LLC director | UTender of shares Common Stockindirect: See Footnote | -3,099,265 | - | - | 0 | Aug 12, 2025 |
| Aug 8, 2025 | Versant Ventures V, LLC owner | UTender of shares Common Stockindirect: By Versant Venture Capital V, L.P. | -2,726,322 | - | - | 0 | Aug 12, 2025 |
| Aug 8, 2025 | Versant Ventures V, LLC owner | UTender of shares Common Stockindirect: By Versant Venture Capital V (Canada) LP | -207,486 | - | - | 0 | Aug 12, 2025 |
| Aug 8, 2025 | Versant Ventures V, LLC owner | UTender of shares Common Stockindirect: By Versant Ophthalmic Affiliates Fund I, L.P. | -90,888 | - | - | 0 | Aug 12, 2025 |
| Aug 8, 2025 | Versant Ventures V, LLC owner | UTender of shares Common Stockindirect: By Versant Affiliates Fund V, L.P. | -82,006 | - | - | 0 | Aug 12, 2025 |
| Aug 8, 2025 | Versant Ventures V, LLC owner | UTender of shares Common Stockindirect: By Versant Vantage II, L.P. | -274,990 | - | - | 0 | Aug 12, 2025 |
| Aug 8, 2025 | Rishi Gupta director | UTender of shares Common Stockindirect: See Footnotes | -3,099,265 | - | - | 0 | Aug 8, 2025 |
| Aug 8, 2025 | Davis Jerel director | UTender of shares Common Stockindirect: By Versant Vantage II, L.P. | -274,990 | - | - | 0 | Aug 8, 2025 |
| Aug 8, 2025 | Davis Jerel director | UTender of shares Common Stockindirect: By Versant Venture Capital V, L.P. | -2,726,322 | - | - | 0 | Aug 8, 2025 |
| Aug 8, 2025 | Davis Jerel director | UTender of shares Common Stockindirect: By Versant Venture Capital V (Canada) LP | -207,486 | - | - | 0 | Aug 8, 2025 |
| Aug 8, 2025 | Davis Jerel director | UTender of shares Common Stockindirect: By Versant Ophthalmic Affiliates Fund I, L.P. | -90,888 | - | - | 0 | Aug 8, 2025 |
| Aug 8, 2025 | Davis Jerel director | UTender of shares Common Stockindirect: By Versant Affiliates Fund V, L.P. | -82,006 | - | - | 0 | Aug 8, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Rishi Guptadirector, owner
- Davis Jereldirector
- Orbimed Advisors LLCdirector, owner
- Versant Ventures V, LLCowner
Questions about TSBX
Answered from the filings on this page, as of the latest one.
Are insiders buying TSBX?
No. In the last 90 days no insider at Turnstone Biologics Corp. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade TSBX on the open market?
No open-market trade has been scored at Turnstone Biologics Corp.. The latest Form 4 on file was filed on Aug 12, 2025 and holds grants, exercises or other rows that are not market trades.
How many insiders file Form 4 at Turnstone Biologics Corp.?
4 people have filed a Form 4 at Turnstone Biologics Corp., among them Rishi Gupta (director and 10% owner), Davis Jerel (director), Orbimed Advisors LLC (director and 10% owner). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.